Mefenamic Acid - CAS 61-68-7
Catalog number: 61-68-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C15H15NO2
Molecular Weight:
241.29
COA:
Inquire
Targets:
Cox-2 | COX
Description:
A competitive inhibitor of COX-1 and COX-2
Brife Description:
A competitive inhibitor of COX-1 and COX-2
Appearance:
Off-White to Pale Yellow Solid
Synonyms:
CI 473; CN-35355; CI473; CN35355; CI-473; CN 35355; Benzoic acid, 2-[(2,3-dimethylphenyl)amino]-
Solubility:
DMSO 48 mg/mL (198.93 mM); Water <1 mg/mL (<1 mM)
Storage:
3 years -20°C powder;6 months-80°C in solvent
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Grams-Kilos
Melting Point:
227-229°C
InChIKey:
HYYBABOKPJLUIN-UHFFFAOYSA-N
InChI:
1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
Canonical SMILES:
CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C
1.Comparison the effect of mefenamic acid and Teucrium polium on the severity and systemic symptoms of dysmenorrhea.
Abadian K1, Keshavarz Z2, Mojab F3, Alavi Majd H4, Abbasi NM3. Complement Ther Clin Pract. 2016 Feb;22:12-5. doi: 10.1016/j.ctcp.2015.09.003. Epub 2015 Sep 25.
BACKGROUND: Primary dysmenorrhea is a prevalent problem and its effects decrease the quality of life in many women across the world. The aim of this study was to research the effect of Teucrium polium compared to mefenamic acid on primary dysmenorrhea.
2.Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.
Nurhikmah W1, Sumirtapura YC1, Pamudji JS1. Sci Pharm. 2016 Feb 14;84(1):181-90. doi: 10.3797/scipharm.ISP.2015.09. eCollection 2016.
Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that is widely used for the treatment of mild-to-moderate pain. Mefenamic acid belongs to the Biopharmaceutical Classification System (BCS) class II drug which has lower water solubility but high permeability. There are two different compendial methods available for dissolution tests of mefenamic acid solid dosage forms, i.e. methods of United States Pharmacopeia 37 (USP) and Pharmacopoeia of the People's Republic of China 2010 (PPRC). Indonesian Pharmacopeia V ed. (FI) adopted the USP method. On the other hand, many researches focused on the use of a 'biorelevant' medium to develop the dissolution test method. The aim of this research was to study the dissolution profile of mefenamic acid from its solid dosage forms (caplet and capsule) available in the Indonesian market with three different dissolution medium: USP, PPRC, and biorelevant fasted simulated small intestinal fluid (FaSSIF) media.
3.Immunomodulatory activity of mefenamic acid in mice models of cell-mediated and humoral immunity.
Shabbir A1, Arshad HM1, Shahzad M2, Shamsi S1, Ashraf MI2. Indian J Pharmacol. 2016 Mar-Apr;48(2):172-8. doi: 10.4103/0253-7613.178837.
OBJECTIVES: Previously, different nonsteroidal anti-inflammatory drugs (NSAIDs) have been evaluated for their potential immunomodulatory activities. Mefenamic acid is a well-known NSAID and is used in the treatment of musculoskeletal disorders, inflammation, fever, and pain. To the best of our knowledge, promising data regarding the immunomodulatory activity of mefenamic acid is scarce. Current study investigates the immunomodulatory activity of mefenamic acid in different models of cell-mediated and humoral immunity.
4.Aqueous chlorination of mefenamic acid: kinetics, transformation by-products and ecotoxicity assessment.
Adira Wan Khalit WN1, Tay KS1. Environ Sci Process Impacts. 2016 Apr 9. [Epub ahead of print]
Mefenamic acid (Mfe) is one of the most frequently detected nonsteroidal anti-inflammatory drugs in the environment. This study investigated the kinetics and the transformation by-products of Mfe during aqueous chlorination. The potential ecotoxicity of the transformation by-products was also evaluated. In the kinetic study, the second-order rate constant (kapp) for the reaction between Mfe and free available chlorine (FAC) was determined at 25 ± 0.1 °C. The result indicated that the degradation of Mfe by FAC is highly pH-dependent. When the pH was increased from 6 to 8, it was found that the kapp for the reaction between Mfe and FAC was decreased from 16.44 to 4.4 M-1 s-1. Characterization of the transformation by-products formed during the chlorination of Mfe was carried out using liquid chromatography-quadrupole time-of-flight accurate mass spectrometry. Four major transformation by-products were identified. These transformation by-products were mainly formed through hydroxylation, chlorination and oxidation reactions.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cox-2 Products


CAS 36062-05-2 Hexahydrocurcumin

Hexahydrocurcumin
(CAS: 36062-05-2)

Extract from the rhizomes of Curcuma longa L, shows cytotoxic effect, may prove useful in cancer prevention.

CAS 50-78-2 Aspirin

Aspirin
(CAS: 50-78-2)

A salicylate and irreversible COX1 and COX2 inhibitor

CAS 4394-00-7 Niflumic Acid

Niflumic Acid
(CAS: 4394-00-7)

A selective COX-2 inhibitor; GPR35 activator; Cox-2: IC50 = 918 nM (human); Cox-1: IC50 = 1.06 µM (human); GPR35: IC50 = 1.28 µM (human)

CAS 42461-84-7 Flunixin Meglumin

Flunixin Meglumin
(CAS: 42461-84-7)

Flunixin is a non-steroidal anti-inflammatory drug (NSAID), analgesic, and antipyretic used in horses, cattle and pigs. It is often formulated as the meglumine ...

CAS 202409-33-4 Etoricoxib

Etoricoxib
(CAS: 202409-33-4)

A selective COX-2 inhibitor

CAS 170569-86-5 SC-236

SC-236
(CAS: 170569-86-5)

A potent, selective COX-2 inhibitor

CAS 53716-49-7 Carprofen

Carprofen
(CAS: 53716-49-7)

A COX-2 inhibitor; A non-steroidal anti-inflammatory drug

CAS 154355-75-6 COX/5-LO-IN-1

COX/5-LO-IN-1
(CAS: 154355-75-6)

A dual inhibitor of cylooxygenase and 5-lipoxygenase

Chemical Structure

CAS 61-68-7 Mefenamic Acid

Quick Inquiry

Verification code

Featured Items